X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.05. On average, analysts expect X4 Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

X4 Pharmaceuticals Trading Down 1.3 %

X4 Pharmaceuticals stock traded down $0.02 during trading on Wednesday, hitting $1.11. The company had a trading volume of 3,544,259 shares, compared to its average volume of 2,595,171. X4 Pharmaceuticals has a 1-year low of $0.57 and a 1-year high of $2.58. The company has a current ratio of 5.34, a quick ratio of 5.34 and a debt-to-equity ratio of 1.07. The company's 50 day simple moving average is $1.15 and its 200-day simple moving average is $0.93. The stock has a market cap of $185.57 million, a price-to-earnings ratio of -1.84 and a beta of 0.49.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares in the company, valued at $53,025. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares in the company, valued at $53,025. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Paula Ragan sold 49,678 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now owns 765,068 shares in the company, valued at $673,259.84. The disclosure for this sale can be found here. Insiders sold a total of 185,708 shares of company stock valued at $170,428 over the last ninety days. Insiders own 1.08% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their price target on shares of X4 Pharmaceuticals from $3.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.